Apremilast (Otezla, Celgene®, Summit, NJ, USA), a PDE4 inhibitor approved for use in psoriatic arthritis and Behçet’s disease, has been evaluated in a phase II, double-blind, placebo-controlled RCT in UC [46]. The gene discussed is PDE4A; the disease is psoriatic arthritis.